These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12599228)

  • 21. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0.
    Tilly W; Gellermann J; Graf R; Hildebrandt B; Weissbach L; Budach V; Felix R; Wust P
    Strahlenther Onkol; 2005 Jan; 181(1):35-41. PubMed ID: 15660191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
    deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
    Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
    Lin AM; Rini BI; Weinberg V; Fong K; Ryan CJ; Rosenberg JE; Fong L; Small EJ
    BJU Int; 2006 Oct; 98(4):763-9. PubMed ID: 16796694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
    BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.
    Pantuck AJ; Leppert JT; Zomorodian N; Aronson W; Hong J; Barnard RJ; Seeram N; Liker H; Wang H; Elashoff R; Heber D; Aviram M; Ignarro L; Belldegrun A
    Clin Cancer Res; 2006 Jul; 12(13):4018-26. PubMed ID: 16818701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
    Schröder FH; Roobol MJ; Boevé ER; de Mutsert R; Zuijdgeest-van Leeuwen SD; Kersten I; Wildhagen MF; van Helvoort A
    Eur Urol; 2005 Dec; 48(6):922-30; discussion 930-1. PubMed ID: 16263208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of calcitriol on prostate-specific antigen in vitro and in humans.
    Beer TM; Garzotto M; Park B; Mori M; Myrthue A; Janeba N; Sauer D; Eilers K
    Clin Cancer Res; 2006 May; 12(9):2812-6. PubMed ID: 16675575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage radiation for a rising PSA following radical prostatectomy.
    Maier J; Forman J; Tekyi-Mensah S; Bolton S; Patel R; Pontes JE
    Urol Oncol; 2004; 22(1):50-6. PubMed ID: 14969805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
    Bajaj GK; Zhang Z; Garrett-Mayer E; Drew R; Sinibaldi V; Pili R; Denmeade SR; Carducci MA; Eisenberger MA; DeWeese TL
    Urology; 2007 Mar; 69(3):526-31. PubMed ID: 17382158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perineal salvage prostatectomy for radiation resistant prostate cancer.
    van der Poel HG; Beetsma DB; van Boven H; Horenblas S
    Eur Urol; 2007 Jun; 51(6):1565-71; discussion 1572. PubMed ID: 16949728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate.
    Amato RJ; Hernandez-McClain J; Henary H
    Urol Oncol; 2009; 27(1):8-13. PubMed ID: 18367123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era.
    Lin DD; Schultz D; Renshaw AA; Rubin MA; Richie JP; D'Amico AV
    Urology; 2005 Mar; 65(3):528-32. PubMed ID: 15780370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The promiscuous receptor.
    Newsom-Davis TE; Kenny LM; Ngan S; King J; Waxman J
    BJU Int; 2009 Nov; 104(9):1204-7. PubMed ID: 19426197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
    J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
    Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
    Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
    J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.